Blog: ALLARITY THERAPEUTICS, INC. : Changes in Registrant’s Certifying Accountant, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 4.01 Changes in Registrant’s Certifying Accountant

(b) On September 9, 2022, the Audit Committee of the Board of Directors of the
Allarity Therapeutics, Inc. (the “Company”) approved the engagement of Wolf &
Company, P.C. (“Wolf & Company”) as its independent registered public accounting
firm for the fiscal year ending December 31, 2022, effective immediately.

During the two most recent fiscal years ended December 31, 2020 and December 31,
2021 and through the subsequent interim period to September 9, 2022, neither the
Company, nor anyone on its behalf, consulted with Wolf & Company regarding any
accounting or auditing issues involving the Company, including (i) the
application of accounting principles to a specified transaction, either
completed or proposed, or the type of audit opinion that might be rendered with
respect to the consolidated financial statements of the Company; or (ii) any
matter that was the subject of a “disagreement” (as defined in Item
304(a)(1)(iv) of Regulation S-K and the related instructions) or a “reportable
event” (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).

Item 7.01 Regulation FD Disclosure

On September 12, 2022, the Company issued a press release announcing the
engagement of Wolf & Company. A copy of the press release is attached as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

This information is furnished pursuant to Item 7.01 of Form 8-K and shall not be
deemed to be “filed” for the purposes of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that Section, unless we
specifically incorporate it by reference in a document filed under the
Securities Act of 1933 or the Securities Exchange Act of 1934. By furnishing
this information on this Current Report on Form 8-K, we make no admission as to
the materiality of any information in this report that is required to be
disclosed solely by reason of Regulation FD.

Item 9.01.  Financial Statements and Exhibits

(d) Exhibits

Exhibit    Exhibit Descri5ption
99.1         Press Release dated September 12, 2022
104        Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s